Abbott Laboratories (ABT)
-NYSE | Prev Close: | 33.78 |
|---|
| Open: | N/A |
|---|
| Bid: | 33.28 x 300 |
|---|
| Ask: | 33.68 x 100 |
|---|
| 1y Target Est: | 40.44 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 16-Oct-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 30.05 - 38.77 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 7,290,520 |
|---|
| Market Cap: | 52.50B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Why October 1, 2013, matters to medical device industry stocksMarket Realist(Tue, Oct 1)
- Why device makers will add value to products, driving up revenuesMarket Realist(Tue, Oct 1)
- Merck Restructuring Plan To Save $2.5 Bil Lifts Stockat Investor's Business Daily(Tue, Oct 1)
- J&J receives private equity offers for diagnostics unit -sourcesReuters(Mon, Sep 30)
- Fundamental Value Investing: An Interview with Eric Kallen, President and Chief Investment Strategist at Hayek Kallen Investment Management, LLC.Wall Street Transcript(Mon, Sep 30)
- [$$] DexCom, Insulet Unmoved by Medtronicat Barrons.com(Mon, Sep 30)
- Abbott Labs' Dissolving Heart Stent Helps Improve Recoveryat BusinessWeek(Mon, Sep 30)
- Why medical device companies’ federal contracts will boost stocksMarket Realist(Mon, Sep 30)
- 5 Relatively Undervalued Dividend Fat Cats That Offer Reliable Retirement Incomeat Seeking Alpha(Sun, Sep 29)
- 2 Big Approvals Med Tech Investors Need to Knowat Motley Fool(Fri, Sep 27)
- David And Goliath Case Offers A Surprising Opportunityat Seeking Alpha(Thu, Sep 26)
- Must-know: The medical device tax repeal is closer than everMarket Realist(Thu, Sep 26)
- Will 3 Versions of Pfizer Be More Valuable Than 1?at Motley Fool(Wed, Sep 25)
- Why the domestic medical device industry’s growth is slowingMarket Realist(Wed, Sep 25)
- Abbott Hosts Conference Call for Third-Quarter EarningsPR Newswire(Wed, Sep 25)
Key Statistics
| Forward P/E (1 yr): | 15.15 |
|---|
| P/S (ttm): | 1.31 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.01 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 0.52 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | 1.42 |
|---|
Business Summary
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine ins...
View More